Amisulpride is indicated for:
Irrespective of gender only Adults (18 - 65 years old)
Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Amisulpride is contraindicated in the following cases:
Amisulpride is eliminated by the renal route. In renal insufficiency, the dose should be reduced to half in patients with creatinine clearance (CRCL) between 30-60 ml/min and to a third in patients with CRCL between 10-30 ml/min. As there is no experience in patients with severe renal impairment (CRCL <10 ml/min) particular care is recommended in these patients.
Amisulpride is contraindicated in breast cancer. Amisulpride may increase prolactin levels. Therefore, caution should be exercised and patients with a history or a family history of breast cancer should be closely monitored during aisulpride therapy.
Amisulpride may oppose the effect of dopamine agonists e.g. bromocriptine, ropinirole.
Reciprocal antagonism of effects between levodopa and neuroleptics. Amisulpride may oppose the effect of dopamine agonists e.g. bromocriptine, ropinirole.
Amisulpride is contraindicated in pituitary gland prolactinomas. Amisulpride may increase prolactin levels. Cases of benign pituitary tumours such as prolactinoma have been observed during amisulpride therapy. In case of very high levels of prolactin or clinical signs of pituitary tumour (such as visual field defect and headache), pituitary imaging should be performed. If the diagnosis of pituitary tumour is confirmed, the treatment with amisulpride must be stopped.
Amisulpride is contraindicated in phaeochromocytoma.